newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

  • Ascentage Pharma Group International announced 17 clinical advances regarding its core assets will be presented at the 31st Congress of the European Hematology Association (EHA2026).
  • The EHA2026 Congress is scheduled to convene in Stockholm, Sweden, from June 11 to 14, 2026, featuring 8 poster presentations among other abstracts.
  • Key data presented focuses on Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor, & Lisaftoclax (APG-2575), the first China-developed Bcl-2 selective inhibitor.
  • Abstract PS1733 details updated efficacy & safety of Olverembatinib as second-line therapy for chronic-phase chronic myeloid leukemia (CP-CML).
  • Abstract PS1727 covers Olverembatinib efficacy in CP-CML patients with prior resistance to ponatinib or asciminib & ASXL1 mutations.
  • Abstract PS1479 presents updated results of the POLARIS-1 Phase 3 study on Olverembatinib combined with low-intensity chemotherapy for newly diagnosed Ph+ ALL.
  • Abstract PS1713 examines the correlation of baseline characteristics with prognosis in CLL/SLL patients treated with Lisaftoclax in a pivotal Phase 2 study.
  • Abstract PS1473 reports safety & preliminary efficacy of Olverembatinib combined with Lisaftoclax in pediatric patients with relapsed/refractory Ph+ ALL from a Phase 1B study.
  • All abstracts are available on the EHA website, with a note that Olverembatinib & Lisaftoclax are not yet approved by the FDA in the US.
  • Ascentage Pharma is conducting multiple global registrational Phase 3 trials, including POLARIS-2 for CML, POLARIS-1 for Ph+ ALL, & POLARIS-3 for SDH-deficient GIST.
  • The company is also conducting four global Phase 3 trials for Lisaftoclax: GLORA, GLORA-2, GLORA-3, & GLORA-4 across various hematologic malignancies.
  • Ascentage Pharma maintains partnerships with major pharmaceutical companies including Takeda, AstraZeneca, Merck, Pfizer, & Innovent, & collaborates with institutions such as Dana-Farber Cancer Institute & Mayo Clinic.